Philip Rawlins2025-04-07T09:00:00
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-31T06:00:00Z
Contributor Dr Davinder Ramsingh, Drug Target Review
2023-09-27T10:36:50
Sponsored by NanoTemper Technologies
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2024-01-24T12:52:38
Sponsored by BellBrook Labs
Site powered by Webvision Cloud